CTLA4 and neoplasm: However, tumors exploit these pathways by aberrantly upregulating immune checkpoint molecules (e.g., CTLA-4 and PD-1 on T cells) or their ligands (e.g., PD-L1 on tumor cells), thereby dampening antitumor immunity.